New drug combo tested to boost immune attack on lung cancer before surgery

This study is testing whether adding a drug called alirocumab to standard pre-surgery treatment (chemotherapy plus an immunotherapy drug, cemiplimab) can help the immune system better recognize and attack early-stage non-small cell lung cancer. About 126 patients with stage 1B-3A lung cancer will be randomly assigned to receive the standard two-drug combination or the new three-drug combination for a few cycles before their planned surgery. The main goal is to see if the three-drug combination leads more patients to have no detectable cancer cells left in their surgically removed tumor.